CG Oncology, Inc. (NASDAQ:CGON) to Post FY2028 Earnings of $1.45 Per Share, HC Wainwright Forecasts

CG Oncology, Inc. (NASDAQ:CGON) – Equities researchers at HC Wainwright increased their FY2028 earnings estimates for shares of CG Oncology in a research note issued on Thursday, April 4th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn $1.45 per share for the year, up from their prior forecast of $1.44. HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for CG Oncology’s current full-year earnings is ($1.60) per share.

Other research analysts also recently issued reports about the company. Morgan Stanley assumed coverage on CG Oncology in a report on Tuesday, February 20th. They set an “overweight” rating and a $55.00 price objective on the stock. Cantor Fitzgerald initiated coverage on CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $75.00 price target on the stock. Finally, The Goldman Sachs Group assumed coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price objective for the company.

CG Oncology Stock Up 1.9 %

CG Oncology stock opened at $38.46 on Friday. The company’s 50 day moving average is $41.11. CG Oncology has a fifty-two week low of $28.55 and a fifty-two week high of $50.23.

Insider Buying and Selling at CG Oncology

In related news, CFO Corleen M. Roche purchased 2,000 shares of the business’s stock in a transaction dated Monday, January 29th. The shares were acquired at an average cost of $19.00 per share, for a total transaction of $38,000.00. Following the acquisition, the chief financial officer now owns 2,000 shares of the company’s stock, valued at approximately $38,000. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CFO Corleen M. Roche purchased 2,000 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was acquired at an average cost of $19.00 per share, with a total value of $38,000.00. Following the completion of the transaction, the chief financial officer now owns 2,000 shares in the company, valued at approximately $38,000. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Decheng Capital Global Life Sc acquired 400,000 shares of the business’s stock in a transaction dated Monday, January 29th. The stock was purchased at an average cost of $19.00 per share, for a total transaction of $7,600,000.00. Following the transaction, the insider now owns 400,000 shares in the company, valued at $7,600,000. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 666,472 shares of company stock valued at $12,662,968.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.